Skip to main content

Advertisement

SpringerLink
Log in

Treatment of familial pancreatic cancer and its precursors

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Approximately 10% of pancreatic cancers are believed to have a familial basis. The familial aggregation of pancreatic cancers provides a unique opportunity to prevent the development of pancreatic cancer, to identify and treat precancerous lesions of the pancreas, and to advance our understanding of the genetic basis for the development of all forms of pancreatic cancer. After appropriate genetic counseling, individuals with a strong family history of pancreatic cancer can now be tested for inherited genetic alterations that are known to increase the risk of pancreatic cancer. These include germline BRCA2, STK11/LKB1, p16/CDKN2A and PRSS1 gene mutations. Individuals with one of these inherited genetic alterations and individuals with a strong family history of pancreatic cancer can be counseled on smoking cessation and possible dietary modifications. Selected individuals, even if they are asymptomatic, can be screened using a combination of endoscopic ultrasound and multidetector computed tomography. Patients found to have a mass lesion in the pancreas would then be candidates for surgical resection. The resection of noninvasive precancers will cure these lesions before they have the opportunity to spread and metastasize. Even with the best early detection efforts, some patients will still be diagnosed with an invasive cancer. Surgical resection of invasive pancreatic cancer is proven to be safe and can provide long-term survival in patients with small, node-negative, and margin-negative cancers. Chemotherapy and radiation therapy are effective in some patients with invasive pancreatic cancer, but these therapies do not usually result in long-term cures. Individuals with a family history of pancreatic cancer may also choose to join a research study such as the National Familial Pancreas Tumor Registry.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54: 8–29.

    Article  PubMed  Google Scholar 

  2. Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Databases: Incidence - SEER 11 Regs + AK Public-Use, Nov 2003 Sub for Expanded Races (1992–2001) and Incidence - SEER 11 Regs Public-Use, Nov 2003 Sub for Hispanics (1992–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. 2004.

  3. Klein AP, Brune K, Petersen GM, et al.: Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64: 2634–2638. This paper demonstrates that individuals with a strong family history of pancreatic cancer are more likely to develop pancreatic cancer.

    Article  PubMed  CAS  Google Scholar 

  4. Murphy KM, Brune KA, Griffin CA, et al.: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17%. Cancer Res 2002, 62: 3789–3793.

    PubMed  CAS  Google Scholar 

  5. Ozcelik H, Schmocker B, DiNicola N, et al.: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997, 16: 17–18.

    Article  PubMed  CAS  Google Scholar 

  6. Lynch HT, Brand RE, Lynch JF, et al.: Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 2000, 119: 1756–1760.

    Article  PubMed  CAS  Google Scholar 

  7. Giardiello FM, Welsh SB, Hamilton SR, et al.: Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987, 316: 1511–1514.

    Article  PubMed  CAS  Google Scholar 

  8. Lowenfels AB, Maisonneuve EP, Dimagno YE, et al.: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997, 89: 442–446.

    Article  PubMed  CAS  Google Scholar 

  9. Lynch HT, Voorhees GJ, Lanspa SJ, et al.: Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985, 52: 271–273.

    PubMed  CAS  Google Scholar 

  10. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al.: Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med 2004, 1: e65.

    Article  PubMed  Google Scholar 

  11. Klein AP, Beaty TH, Bailey-Wilson JE, et al.: Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002, 23: 133–149. In this study segregation analysis is used to demonstrate that a major gene is the most likely explanation for the familial aggregation of pancreatic cancer.

    Article  PubMed  Google Scholar 

  12. Michaud DS, Giovannucci E, Willett WC, et al.: Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001, 286: 921–929.

    Article  PubMed  CAS  Google Scholar 

  13. Cuzick J, Babiker AG: Pancreatic cancer, alcohol, diabetes mellitus and gallbladder disease. Int J Cancer 1989, 43: 415–421.

    Article  PubMed  CAS  Google Scholar 

  14. Canto MI, Goggins M, Yeo CJ, et al.: Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. In press. This study demonstrates that asymptomatic individuals with a strong family history of pancreatic cancer can be screened for premalignant neoplasms.

  15. Sohn TA, Yeo CJ, Lillemoe KD, et al.: Resected adenocarcinoma of the pancreas - 616 patients: Results, outcome, and prognostic indications. J Gastroenterol Surg 2000, 4: 567–579.

    Article  CAS  Google Scholar 

  16. Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120: 899–903.

    PubMed  CAS  Google Scholar 

  17. Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230: 776–782.

    Article  PubMed  CAS  Google Scholar 

  18. Chakravarthy A, Abrams RA, Yeo CJ, et al.: Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys 2000, 48: 1089–1096.

    Article  PubMed  CAS  Google Scholar 

  19. Allen AM, Zalupski MM, Robertson JM, et al.: Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 2004, 59: 1461–1467.

    Article  PubMed  CAS  Google Scholar 

  20. Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004, 350: 1200–1210.

    Article  PubMed  CAS  Google Scholar 

  21. Jaffee EM, Hruban RH, Biedrzycki B, et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19: 145–156.

    PubMed  CAS  Google Scholar 

  22. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003, 185: 476–480.

    Article  PubMed  Google Scholar 

  23. Burris HA, III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15: 2403–2413.

    PubMed  CAS  Google Scholar 

  24. Heinemann V, Quietzsch D, Gieseler M, et al.: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma [abstract]. Proc ASCO 2003, 22: 250.

    Google Scholar 

  25. Rocha Lima CMS, Rotche R, Jeffery M, et al.: A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pst) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy [abstract]. Proc ASCO 2003, 22: 251.

    Google Scholar 

  26. Tempero M, Plunkett W, Ruiz VH, et al.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21: 3402–3408.

    Article  PubMed  CAS  Google Scholar 

  27. Louvet C, Labianca R, Hammel P, et al.: GemOx (Gemcitabine + Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III [abstract 4008]. Proc ASCO 2004, 22: 314.

    Google Scholar 

  28. Cheverton P, Friess H, Andras C, et al.: Phase III results of exatecan (CX-8951f) versus gemcitabine (Gem) in chemotherapy-naive patients with advanced pancreatic cancer (APC) [abstract 4005]. Proc ASCO 2004, 23: 314.

    Google Scholar 

  29. Richards DA, Kindler HL, Oettle H, et al.: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer [abstract 4007]. Proc ASCO 2004, 23: 314.

    Google Scholar 

  30. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004, 22: 2610–2616.

    Article  PubMed  CAS  Google Scholar 

  31. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared to gemcitabine along in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [abstract 1]. Proc GI Am Soc Clin Oncol 2005, 24:1.

    Google Scholar 

  32. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA: Costeffectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003, 57: 23–29.

    Article  PubMed  Google Scholar 

  33. Yeo CJ, Yeo TP, Hruban RH, et al.: Cancer of the pancreas. In Cancer: Principles and Practice in Oncology, edn 7. Edited by DeVita, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams and Wilkins; 2005: 945–986. A comprehensive and up-to-date summary of pancreatic cancer from genetics to diagnosis to treatment.

    Google Scholar 

  34. Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002, 236: 355–366.

    Article  PubMed  Google Scholar 

  35. Shi C, Eshleman SH, Jones D, et al.: LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004, 1: 141–147.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, 401 North Broadway, Weinberg 2249, 21231, Baltimore, MD, USA

    Ralph H. Hruban MD, Marcia I. Canto MD, Constance Griffin MD, Scott E. Kern MD, Alison P. Klein PhD, Dan Laheru MD & Charles J. Yeo MD

Authors
  1. Ralph H. Hruban MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcia I. Canto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Constance Griffin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Scott E. Kern MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alison P. Klein PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dan Laheru MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charles J. Yeo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hruban, R.H., Canto, M.I., Griffin, C. et al. Treatment of familial pancreatic cancer and its precursors. Curr Treat Options Gastro 8, 365–375 (2005). https://doi.org/10.1007/s11938-005-0039-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-005-0039-3

Keywords

Search

Navigation